

Sreedar Subramanian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5498373/publications.pdf>

Version: 2024-02-01

66
papers

1,108
citations

430874

18
h-index

414414

32
g-index

66
all docs

66
docs citations

66
times ranked

1927
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1434-1437.	3.7	202
2	Perspective: Vitamin D deficiency and COVID-19 severity " plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. <i>Journal of Internal Medicine</i> , 2021, 289, 97-115.	6.0	185
3	Replication of Colonic Crohn's Disease Mucosal <i>Escherichia coli</i> Isolates within Macrophages and Their Susceptibility to Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 427-434.	3.2	92
4	Bacteria in the pathogenesis of inflammatory bowel disease. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 475-484.	3.1	66
5	Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?. <i>Gut</i> , 2017, 66, 362-381.	12.1	65
6	Vitamin D and COVID-19: evidence and recommendations for supplementation. <i>Royal Society Open Science</i> , 2020, 7, 201912.	2.4	54
7	Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1341-1352.	3.7	46
8	COVID-19 mortality increases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin D. <i>BMJ Nutrition, Prevention and Health</i> , 2020, 3, 118-120.	3.7	41
9	Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 99-104.	1.9	38
10	Infliximab induction regimens in steroid refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 675-683.	3.7	32
11	Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 640-646.	1.3	29
12	Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1436-1446.	1.3	29
13	Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 271-276.	1.6	28
14	From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 88-89.	8.1	26
15	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	8.1	23
16	Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1119-1128.	2.3	22
17	Serum galectins as potential biomarkers of inflammatory bowel diseases. <i>PLoS ONE</i> , 2020, 15, e0227306.	2.5	20
18	Letter: low population mortality from COVID-19 in countries south of latitude 35° North supports vitamin D as a factor determining severity. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 412-413.	3.7	18

#	ARTICLE	IF	CITATIONS
19	Vitamin D and COVID-19 Revisited. <i>Journal of Internal Medicine</i> , 2022, 292, 604-626.	6.0	15
20	Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1367-1377.	4.7	12
21	Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2019, 34, 185-188.	2.2	9
22	Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1902-1907.	1.9	6
23	How to manage: acute severe colitis. <i>Frontline Gastroenterology</i> , 2022, 13, 64-72.	1.8	5
24	Letter: Covid-19 re-initiating clinical services for chronic gastrointestinal diseases. How and when?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1414-1415.	3.7	5
25	Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1236-1240.	3.7	5
26	Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000763.	2.7	4
27	Editorial: intravenous to subcutaneous vedolizumab switch without glitch!. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 349-350.	3.7	4
28	OC-072...The Toppic Trial: A Randomised, Double-Blind Parallel Group Trial of Mercaptopurine VS Placebo to Prevent Recurrence of Crohn's Disease Following Surgical Resection in 240 Patients. <i>Gut</i> , 2016, 65, A43.2-A44.	12.1	3
29	Infliximab in acute severe colitis: getting the right dose. <i>Frontline Gastroenterology</i> , 2020, 11, 427-429.	1.8	3
30	P496 Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S480-S481.	1.3	3
31	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. <i>Gut</i> , 2022, 71, 661-664.	12.1	3
32	PWE-114...The Ibd-control Questionnaire: Multi-centre Validation Plus Evaluation In Routine Care. <i>Gut</i> , 2014, 63, A174.2-A175.	12.1	2
33	P100 Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S137-S138.	1.3	2
34	Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1794-1795.	1.3	2
35	Ambulatory Management of Acute Severe Ulcerative Colitis: A Pandemic-driven Initiative. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e112-e113.	1.9	2
36	Editorial: vedolizumab in inflammatory bowel diseases less is more?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 443-444.	3.7	2

#	ARTICLE	IF	CITATIONS
37	PTH-171â€¦Colonoscopy Performance in Extended Three Session Working Days. Gut, 2013, 62, A281.1-A281.	12.1	1
38	P586 Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohnâ€™s disease: a multi-centre retrospective cohort study. Journal of Crohn's and Colitis, 2019, 13, S407-S408.	1.3	1
39	P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?. Journal of Crohn's and Colitis, 2020, 14, S286-S288.	1.3	1
40	Editorial: endoscopic inflammation in ileoanal pouchesâ€™ does it really matter?. Alimentary Pharmacology and Therapeutics, 2020, 51, 170-171.	3.7	1
41	From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohnâ€™s disease. Scandinavian Journal of Gastroenterology, 2020, 55, 148-153.	1.5	1
42	OC-009â€¦Characterisation and outcome of patients with infliximab induced lupus erythematosus and retreatment with a second anti-tumour necrosis factor agent.. Gut, 2010, 59, A4.2-A4.	12.1	0
43	PWE-091â€¦Crohnâ€™s Disease Monocyte-derived Macrophages Exhibit Equivalent Responses To Intramacrophage Bacterial Infection Relative To Healthy Controls. Gut, 2014, 63, A163.2-A164.	12.1	0
44	PTU-068â€¦Efficacy And Safety Of Granulocyte, Monocyte/macrophage Adsorptive Apheresis In Steroid-dependent Active Uc With Insufficient Response Or Intolerance To Immunosuppressants And/or Biological Therapies (the Art Trial): Week 12 Results. Gut, 2014, 63, A68.1-A68.	12.1	0
45	PWE-100â€¦Increasing Weight And Body Mass Index Adversely Affect Thioguanine Nucleotide Levels In Inflammatory Bowel Disease: Abstract PWE-100 Table 1. Gut, 2014, 63, A168.1-A168.	12.1	0
46	PTH-070â€™Patients receiving anti-tnf agents for inflammatory bowel disease: exposure to diagnostic ionising radiation and trends in imaging modalities. Gut, 2015, 64, A437.1-A437.	12.1	0
47	PTU-335â€™Quality of care in the management of inflammatory bowel disease: how do patients rate their quality of care?: Abstract PTU-335 Table 1. Gut, 2015, 64, A209.2-A210.	12.1	0
48	PWE-062â€¦Effectiveness and safety of vedolizumab (vdz) in ibd patients: a multicentre experience of â€™real world dataâ€™ from the uk. , 2017, , .		0
49	Editorial: the <scp>IBD</scp>â€™disability indexâ€™ ready for prime time?. Alimentary Pharmacology and Therapeutics, 2018, 47, 298-299.	3.7	0
50	Editorial: mitigating primary nonresponse to infliximabâ€™are we better equipped now?. Alimentary Pharmacology and Therapeutics, 2018, 47, 434-435.	3.7	0
51	P093 CD4 T-cell transcriptome analysis at baseline predicts clinical remission to anti-TNF agents in ulcerative colitis (UC). Journal of Crohn's and Colitis, 2019, 13, S132-S133.	1.3	0
52	Editorial: accelerated infliximab inductionâ€™it's time to settle the debate! Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1061-1062.	3.7	0
53	P423 Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S321-S321.	1.3	0
54	Recurrent colonic polyps. Gut, 2020, , gutjnl-2020-323133.	12.1	0

#	ARTICLE	IF	CITATIONS
55	Unexpected cause of dysphagia. BMJ Case Reports, 2021, 14, e242339.	0.5	0
56	Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 2021, , .	2.7	0
57	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
58	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
59	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
60	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
61	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
62	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
63	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
64	Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306.		0
65	Letter: population mortality from COVID-19 and latitude data from China. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1261-1262.	3.7	0
66	Letter: propensity score handle with care. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 362-363.	3.7	0